Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Sarcoma 2Recurrence 2Neoplasms 2Glioma 2Wilms Tumor 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Esophageal Neoplasms 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 19Paclitaxel 18Fluorouracil 16Cisplatin 16pembrolizumab 15Radiotherapy 14Oxaliplatin 12Irinotecan 12Capecitabine 12Cyclophosphamide 10Radiation 8Leucovorin 8Docetaxel 8fludarabine 6Taxes 6Gemcitabine 6Trastuzumab 5fludarabine phosphate 4aldesleukin 4LY6K protein, human 4Fluorodeoxyglucose F18 4Erlotinib Hydrochloride 4Bevacizumab 4spartalizumab 3Surgical Procedures, Operative 3S 1 (combination) 3Pemetrexed 3Nivolumab 3Drug Therapy 3zimberelimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Esophageal Neoplasms × CLR1404 × Clear all
NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡